IPWatchdog LIVE 2026: Dates Set, But What's the Real Draw?
The annual IPWatchdog LIVE conference has announced its 2026 dates and venue. While the logistics are set, the enduring value proposition for attendees remains the key question.
Elon Musk's legal battle with OpenAI is over, but the real story is how these AI titans are shaping our future – from the battlefield to your daily tech. Don't get lost in the PR; here's what's actually happening.
The annual IPWatchdog LIVE conference has announced its 2026 dates and venue. While the logistics are set, the enduring value proposition for attendees remains the key question.
The USPTO's commitment to transparency is once again under fire as allegations surface regarding secret review programs that mirror the infamous SAWS system. Applicants are being kept in the dark, their patent applications allegedly sidelined without proper notification.
The race for AI dominance isn't won by patents alone. It's a whole new game, and the winning strategy starts with understanding value itself.
Freshfields isn't just dipping its toes into the AI waters; it's diving headfirst. Fresh off a Google announcement, the firm is now forging a significant alliance with Anthropic, signaling a major platform shift for legal services.
Imagine a legal AI assistant that isn't a black box, but a blueprint. Scissero's Suzie Law is rewriting the script, handing the keys to legal professionals.
Opus 2's latest AI push promises integrated insights and case management. But beneath the gloss, the real story is always about adoption and revenue.
Collaborative innovation often overlooks IP's long-term strategic implications, creating hidden risks years down the line. Emily Teesdale offers a stark warning about overlooking post-project confidential information handling.
DraftKings' attempt to invalidate a gaming patent claim has hit a brick wall at the Federal Circuit. The decision underscores the tightrope walk companies face when challenging existing intellectual property.
The Supreme Court's oral arguments in *Hikma Pharmaceuticals USA v. Amarin Pharma, Inc.* have thrown a wrench into expectations for the generic drug industry, hinting at a potential reinforcement of existing patent law rather than a radical overhaul.
The Federal Circuit tossed a Patent Trial and Appeal Board (PTAB) obviousness ruling this week, but threw a curveball by declaring challenges to 'real parties in interest' off-limits for review. This move significantly impacts how patent disputes, particularly those involving entities like Qualcomm and Federal Express, will be handled going forward.
The race for AI dominance isn't won solely through patents. A sophisticated IP strategy must now integrate data rights, licensing, and commercialization from the ground up.
The glowing charts of startup growth might be built on shaky foundations. Y Combinator's CEO is calling for revenue accuracy, and the legal AI world is paying attention.